EDU 34 - ROBIN Oligometastasis (OligoMET) Center: Using Biomarker Correlates from a Prostate Cancer Clinical Trial to Improve Future Outcomes
MODERATOR(S)
Nicole Simone, MD - Thomas Jefferson University
session DESCRIPTION
Metastasis is the final common lethal pathway for most cancer patient's demise and once cancer has metastasized, it was generally considered incurable. We now know the metastatic capacity of cancers behaves along a spectrum of disease that contains an oligometastatic state where metastases are limited. This concept has been transformational in the way the clinical field views metastasis; however, a greater biologic understanding is needed. This in turn will lead to the development of new approaches for using radiation therapy to combat metastases. The NCI U54 ROBIN Oligometastasis (OligoMET) Center was created for greater adoption of radiation oncology concepts, biomarkers, and technologies in the oligometastatic space through academic and/or industrial partnerships. The OligoMET Center uses oligometastatic prostate cancer as our model, but results will inform future treatment planning and trial design in other cancers. This session will delve into breakthrough findings from the ROBIN OligoMET Center. The session will explore how specific biomarkers from prostate cancer clinical trials are used to probe the biological nuances of oligometastatic states, focusing on the effects of radiation on tumor plasticity, metabolic reprogramming, and the immune microenvironment. Radiation oncologists attending this session will gain insights into the emerging paradigm where precise radiation treatments not only target tumors but may also recondition the tumor biology, potentially leading to improved patient outcomes. By examining the intersection of biomarker data and radiation's impact on metastasis, this session paves the way for innovative trial designs and collaborative advancements in treating oligometastatic disease across various cancers.
learning objectives
- Analyze the biology of oligometastatic prostate cancer. Learners will assess how radiation affects tumor plasticity, metabolism, and the immune microenvironment, and integrate biomarker data from clinical trials to inform evaluation and treatment decisions for metastatic disease.
- Evaluate biomarker-driven strategies to enhance radiation efficacy in oligometastatic cancer. Learners will assess findings from the ROBIN OligoMET trials and apply biomarker insights to personalize radiation plans, improve outcomes, and explore broader applications across cancer types.
- Implement strategies to integrate radiation into cancer management for oligometastatic disease. Learners will use biomarkers to guide protocol adjustments and demonstrate the ability to design adaptable, radiation-inclusive treatment plans informed by current metastatic disease biology.
Credits
| AMA PRA Category 1 Credits: | 1.00 |
Presentations
-
08:00am - 08:02am PT
Introductions
Speaker: Nicole Simone, MD - Thomas Jefferson University, Philadelphi -
08:02am - 08:17am PT
Radiation Oncology-Biology Integration Network (ROBIN) - Oligometastasis Center
Speaker: Phuoc Tran, MD, PhD - University of Maryland, Baltimore -
08:17am - 08:32am PT
The Genomic Landscape of Castration-sensitive Prostate Cancer: Biomarkers to Direct Local Therapies
Speaker: Matthew Deek, MD - Rutgers University, New Brunswick -
08:32am - 08:47am PT
Digital Pathology-based Multimodal Artificial Intelligence Biomarker Models in Oligometastatic Castration-sensitive Prostate Cancer
Speaker: Philip Sutera, MD - University of Rochester Medical Center, Rochester -
08:47am - 09:00am PT
Questions and Answers
Speaker: Nicole Simone, MD - Thomas Jefferson University, Philadelphi